| Drug General Information |
| Drug ID |
D0LF0O
|
| Former ID |
DNC008930
|
| Drug Name |
BMS-695735
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Preclinical |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H31ClFN7O
|
| Canonical SMILES |
CC1=C2C(=CC(=C1)C3CCN(CC3)CCCF)NC(=C4C(=CC=NC4=O)NCCN5C<br />=C(C=N5)Cl)N2
|
| InChI |
1S/C26H31ClFN7O/c1-17-13-19(18-4-10-34(11-5-18)9-2-6-28)14-22-24(17)33-25(32-22)23-21(3-7-30-26(23)36)29-8-12-35-16-20(27)15-31-35/h3,7,13-16,18,29,32-33H,2,4-6,8-12H2,1H3/b25-23+
|
| InChIKey |
KPIXLYXGTRJJMP-WJTDDFOZSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Insulin-like growth factor I receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Ovarian steroidogenesis
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanomahsa04010:MAPK signaling pathway
|
|
Regulation of actin cytoskeleton
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascadeP00005:Angiogenesis
|
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junctionglypican_1pathway:Glypican 1 network
|
|
Syndecan-4-mediated signaling events
|
|
N-cadherin signaling events
|
|
FGF signaling pathway
|
|
Reactome
|
IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1R
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophyWP51:Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022289) |
|---|
| REF 2 | J Med Chem. 2008 Oct 9;51(19):5897-900. Epub 2008 Sep 3.Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. |
|---|
